Blog Articles

Phone Follow-Up: from Cameroon to the INR in Boca Raton, July 2017

Phone follow-up of a nurse describing her mother’s improvements in gait, vision, post-stroke pain, hand function, and sensation starting within minutes after treatment at the INR Boca Raton, 22 months after stroke.
See her treatment video here: https://youtu.be/7HNuNSviV-I

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. The method utilized for this indication is off-label. Please see the Terms of Use. Copyright 2017 INR PLLC, all rights reserved.

Improvement in Post-Stroke Pain, Gait, & Vision: from Cameroon to the INR in Boca Raton, July 2017

From Cameroon, Africa, improvements in gait, vision, post-stroke pain, hand function, and sensation starting within minutes after treatment at the INR Boca Raton, 22 months after stroke.
See her phone follow-up video here: https://youtu.be/rluAvqFYHCM

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2017 INR PLLC, all rights reserved.

Rapid Improvement 3 Years After Stroke at the INR, May 2017

Patient and husband, a physician, discuss improvement after stroke treatment at the INR in Boca Raton, Florida, in May 2017.

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. The method utilized for this indication is off-label. Please see the Terms of Use. Copyright 2017 INR PLLC, all rights reserved.

New Neuroinflammation Textbook Chapter 2017

Doctors Ignatowski, Tobinick, and Spengler at the INR, January 2014.

 

 

 

 

 

 

This new book chapter has published in its pre-print version from the new scientific textbook entitled, “Mechanisms of Neuroinflammation” by InTech. Download the free pre-print version here: On Overcoming Barriers to Application of Neuroinflammation Research, Edward Tobinick, Tracey Ignatowski, Robert Spengler. InTech, 2017.

Tobinick E, Ignatowski, T., Spengler, R. On Overcoming Barriers to Application of Neuroinflammation Research. In: Abreu GEA, ed. Mechanisms of Neuroinflammation: InTechOpen; 2017.

Family from Mumbai, India to the INR in 2015 & May 2017

Family from Mumbai, India to the INR in 2015 & May 2017

Family from Mumbai, India on their second visit to the INR, in May 2017. First visit and treatment at the INR was in November 2015, four years after her stroke. The family discusses her neurological improvement after her first treatment at the INR. Her neurological improvement increased month after month and now has been sustained for 1 1/2 years and counting.

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2017 INR PLLC, all rights reserved.

Sustained neurological improvement 2 1/2 years after stroke, April 2017

Treatment at the Institute of Neurological Recovery in Boca Raton, Florida, in April, 2017.

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). Please see the Terms of Use. The method of off-label treatment utilized is a patented invention of the INR. Copyright 2017 INR PLLC, all rights reserved.

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. The method utilized for this indication is off-label. Please see the Terms of Use. Copyright 2017 INR PLLC, all rights reserved.

From Papua New Guinea to the INR Boca Raton: Immediate improvement 18 months after stroke, April 2017

Patient is from Papua New Guinea, where he has been living for more than 17 years. Improvements noted in chronic central post-stroke pain, motor function and balance documented within minutes of treatment, 18 months after stroke. Treatment at the Institute of Neurological Recovery in Boca Raton, Florida on April 13, 2017.

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2017 INR PLLC, all rights reserved.

Study provides new evidence for the efficacy of a TNF inhibitor for relief of persistent sciatica

November 1, 2013: A new randomized study published in the November 1, 2013 issue of the journal Spine (Freeman, B.J., et al., Randomized, Double-blind, Placebo-Controlled, Trial of Transforaminal Epidural Etanercept for the Treatment of Symptomatic Lumbar Disc Herniation. Spine (Phila Pa 1976), 2013. 38(23): p. 1986-94) provides new evidence for the efficacy of a TNF inhibitor for relief of persistent sciatica associated with lumbar disc herniation. Etanercept is a potent anti-inflammatory drug that is a selective blocker of an immune signaling molecule called TNF. Local perilesional methods of administration of etanercept, including epidural injection for treating sciatica associated with lumbar disc herniation were invented by Edward Tobinick M.D. more than a decade earlier (U.S. patent 6,419,944; 6,537,549; and others).

The new Spine study now constitutes the third published favorable clinical trial providing randomized, controlled trial (RCT) data of the efficacy of etanercept for treating sciatica. Dr. Tobinick was the first to publish human data reporting the effectiveness of etanercept for this indication in 2003, with a larger study published in 2004 (Tobinick, E. and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85).

Individual results can vary. See the Terms of Use.  Intractable disc-related low back and neck pain are important medical problems with significant unmet medical need.

Four randomized controlled clinical trials support the efficacy of a TNF inhibitor for disc-related pain

November 4, 2013:

U.S. patent 6,419,944 (inventor Edward Tobinick M.D., filed April 5, 2001) contained the first clinical report of rapid improvement in disc-related pain following the administration of perispinal etanercept. Now, more than a decade later, there are four favorable clinical trials that provide randomized, controlled trial (RCT) data supporting the efficacy of etanercept for treating disc-related pain. In 2013, data from two of these RCTs have been presented: the Nov 1 study by Freeman published in Spine; and the study conducted at Chiba University in Japan(Sainoh, T., et al., Intradiscal Administration of Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, Clinically Improves Intractable Discogenic Low Back Pain: A Prospective Randomized Study, in International Society for the Study of the Lumbar Spine 40th Annual Meeting, May 2013). In 2012 the RCT by Ohtori reported positive etanercept data (Ohtori, S., et al., Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976), 2012. 37(6): p. 439-44). In 2009 the RCT performed at Walter Reed Army Medical Center provided favorable efficacy and human and animal safety data (Cohen, S.P., et al., Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology, 2009. 110(5): p. 1116-26).

 

Judgment is entered in favor of plaintiff TACT IP LLC against defendents Janssen Biotech, Inc. and New York University

August 5, 2013:

On August 5, 2013, in the United States District Court for the Eastern District of Virginia, Alexandria Division, judgment in favor of TACT IP, LLC, holding patents of Edward Tobinick, M.D., was entered:

” Case No. 1:12cv909

JUDGMENT ORDER

Upon consideration of the July 19, 2013 Report and Recommendation of the United States Magistrate Judge designated to conduct a hearing in this matter, no objections having been filed, and upon an independent de novo review of the record, it is hereby ORDERED that the Court adopts as its own the findings of fact and recommendation of the United States Magistrate Judge, as set forth in the June 19, 2013 Report and Recommendation.

Accordingly, it is hereby ORDERED that judgment is ENTERED by default in favor of plaintiff TACT IP LLC and against defendants Janssen Biotech, Inc. and New York University…..”

Edward Tobinick’s issued patents, assigned to TACT IP LLC, include, but are not limited to the following U.S. patents: 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, and 8236306. The patents at issue in the entered judgment in favor of TACT IP LLC included those involving epidural administration of etanercept for treatment of symptomatic lumbar disc herniation.